Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study.
Mycophenolate mofetil (MM) is an immunosuppressive agent developed and originally used to prevent acute rejection of solid-organ transplantation. There have been preliminary reports of its successful use in the treatment of autoimmune myasthenia gravis (MG). We conducted a double-blind, placebo-controlled pilot trial of MM in the treatment of suboptimally controlled, stable MG. Results of this pilot study are promising and suggestive of greater improvement in the patients who received MM compared to placebo.
Department of Neurological Sciences, Rush University and Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA. matthew_m_meriggioli@rush.edu
Matthew N
MN
Meriggioli
Julie
J
Rowin
Judith G
JG
Richman
Sue
S
Leurgans
D000328:Adult; D000368:Aged; D000906:Antibodies / Q000032:analysis; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D009460:Neurologic Examination; D010865:Pilot Projects; D011950:Receptors, Cholinergic / Q000276:immunology; D016896:Treatment Outcome
D000906:Antibodies; D007166:Immunosuppressive Agents; D011950:Receptors, Cholinergic; D009173:Mycophenolic Acid